Effectiveness and Safety of Electroconvulsive Therapy in Adolescents with Schizophrenia and Schizoaffective Disorder: A Clinical Case Series
Journal of Clinical Medicine · 15.12.2025 · 14 (24) · 8880
DOI: 10.3390/jcm14248880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.12.2025. Verfasst von Agnieszka Permoda-Pachuta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroses, Personality Disorders and Eating Disorders, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Electroconvulsive therapy (ECT) is a well-established intervention for severe and treatment-resistant psychiatric disorders, yet its use in adolescents remains limited, particularly in Europe. Data on its safety and effectiveness in this population are scarce. This study aimed to evaluate the clinical outcomes and tolerability of ECT in adolescents diagnosed with schizophrenia and schizoaffective disorder.
Methods
We conducted a retrospective observational case series of 22 adolescents (mean age 16.7 ± 1.3 years) treated with ECT between 2017 and 2024 at a university psychiatric department. Diagnoses included paranoid schizophrenia (n = 15), catatonic schizophrenia (n = 2), and schizoaffective disorder (n = 5). Symptom severity was assessed with the Positive and Negative Syndrome Scale (PANSS) before and after the ECT course. Adverse events were evaluated based on daily clinical monitoring and medical records.
Results
The overall response rate, defined as ≥50% reduction in total PANSS score, was 82% (schizophrenia: 82%; schizoaffective disorder: 80%). Mean PANSS total score decreased from 158.0 ± 22.6 to 72.1 ± 20.7 (p < 0.0001). Improvements were most pronounced in the general psychopathology and positive symptom domains. No serious adverse events were observed. The most common transient side effects were headache (41%), memory complaints (27%), and somnolence (22%).
Conclusions
ECT appears to be an effective and safe treatment option for adolescents with treatment-resistant schizophrenia and schizoaffective disorder. These findings add to the limited European evidence base and support considering ECT earlier in the treatment course of severe adolescent psychosis. Larger, prospective studies with long-term follow-up are warranted to confirm these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroses, Personality Disorders and Eating Disorders, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
- Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, 20-059 Lublin, Poland.
- Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
- Third Department of Psychiatry, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
ORCID-Profile: Piotr Obszański, Monika Dominiak, Adam Gędek
Zitieren
APA
Permoda-Pachuta, A., Obszański, P., Makarewicz, A., Dominiak, M., & Gędek, A. (2025). Effectiveness and Safety of Electroconvulsive Therapy in Adolescents with Schizophrenia and Schizoaffective Disorder: A Clinical Case Series. Journal of Clinical Medicine, 14(24), 8880. https://doi.org/10.3390/jcm14248880
Vancouver
Permoda-Pachuta A, Obszański P, Makarewicz A, Dominiak M, Gędek A. Effectiveness and Safety of Electroconvulsive Therapy in Adolescents with Schizophrenia and Schizoaffective Disorder: A Clinical Case Series. Journal of Clinical Medicine. 2025;14(24):8880. doi:10.3390/jcm14248880
BibTeX
@article{PermodaPachuta2025,
author = {Permoda-Pachuta, Agnieszka and Obszański, Piotr and Makarewicz, Agata and Dominiak, Monika and Gędek, Adam},
title = {Effectiveness and Safety of Electroconvulsive Therapy in Adolescents with Schizophrenia and Schizoaffective Disorder: A Clinical Case Series},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {24},
pages = {8880},
doi = {10.3390/jcm14248880}
}
EUVIMED